Systems, reagents and software to cover broad range of clinical applications
This press release features multimedia. View the full release here:http://www.businesswire.com/news/home/20171115005389/en/
Illumina NextSeq 550Dx (Photo: Business Wire)
NextSeq 550Dx
Assays that are run on the NextSeq 550Dx instrument follow a simple process including sequencing and data analysis. The setup of workflows for different applications are fully integrated in NextSeq 550Dx software. The instrument also offers fully-integrated onboard analysis software with modular software architecture to support current and future assays.
“NGS is beginning to play a significant role in the clinic,” said
For additional information on the NextSeq 550Dx, please visit www.illumina.com/nextseq550dx.
MiSeqDx
The expanded intended use of the MiSeqDx instrument, which was the first
“The expansion and launch of these regulated platforms represent regulatory milestones important to the clinical community,” said
- TruSeq Custom Amplicon Kit Dx
- TruSeq Custom Amplicon Dx – FFPE QC Kit
- MiSeqDx Reagent Kit v3 (2x300)
The MiSeqDx now has the following IVD menu:
- Cystic Fibrosis 139-Variant Assay
- Cystic Fibrosis Sequencing Assay
-
Extended RAS Panel - Germline Variant Module
- Somatic Variant Module
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products such as the NextSeq 550Dx instrument, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171115005389/en/
Source:
Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Tina Amirkiai
858-882-6822
PR@illumina.com